We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+2.06%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$243M
AUM Growth
-$73.5M
(-23%)
Cap. Flow
-$66.1M
Cap. Flow
% of AUM
-27.19%
Top 10 Holdings %
Top 10 Hldgs %
48.94%
Holding
62
New
17
Increased
8
Reduced
19
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$9.14M |
| 2 |
Humana
HUM
|
+$8.85M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.43M |
| 4 |
Viatris
VTRS
|
+$6.68M |
| 5 |
Cerus
CERS
|
+$6.23M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Henry Schein
HSIC
|
+$27.7M |
| 2 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$12.4M |
| 3 |
MSON
Misonix Inc
MSON
|
+$10.1M |
| 4 |
Perrigo
PRGO
|
+$10.1M |
| 5 |
United Therapeutics
UTHR
|
+$9.82M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.43% |
| 2 | Consumer Staples | 3.88% |
| 3 | Consumer Discretionary | 2.26% |
| 4 | Materials | 1.99% |
| 5 | Technology | 1.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Tenet Healthcare
THC
$20.1B
| $16.3M | 6.72% |
200,000
+125,000
| +167% | +$9.14M |
|
2
Pacira BioSciences
PCRX
$1.02B
| $14.4M | 5.94% |
240,000
-135,000
| -36% | -$7.44M |
|
3
Medtronic
MDT
$107B
| $12.9M | 5.32% |
125,000
-75,000
| -38% | -$8.68M |
|
4
Bioventus
BVS
$799M
| $12.7M | 5.21% |
875,000
+395,000
| +82% | +$5.62M |
|
5
SI-BONE Inc
SIBN
$737M
| $12.2M | 5.02% |
550,000
+150,000
| +38% | +$3.23M |
|
6
Rigel Pharmaceuticals
RIGL
$680M
| $11.9M | 4.9% |
450,000
-250,000
| -36% | -$7.54M |
|
7
Lantheus
LNTH
$6.82B
| $10.3M | 4.22% |
355,000
-35,000
| -9% | -$931K |
|
8
AngioDynamics
ANGO
$562M
| $9.52M | 3.91% |
345,000
-5,000
| -1% | -$138K |
|
9
Turning Point Brands
TPB
$1.47B
| $9.45M | 3.88% |
250,000
-25,000
| -9% | -$1.01M |
|
|
10
Humana
HUM
$46.7B
| $9.28M | 3.81% |
+20,000
| New | +$8.85M |
|
|
11
BioMarin Pharmaceuticals
BMRN
$11.5B
| $7.95M | 3.27% |
+90,000
| New | +$7.43M |
|
|
STRM
12
DELISTED
Streamline Health Solutions
STRM
| $7.35M | 3.02% |
328,725
| – | – |
|
13
AtriCure
ATRC
$1.77B
| $6.95M | 2.86% |
100,000
-17,000
| -15% | -$1.24M |
|
|
14
Cerus
CERS
$587M
| $6.81M | 2.8% |
1,000,000
+925,000
| +1,233% | +$6.23M |
|
|
15
Viatris
VTRS
$20.1B
| $6.76M | 2.78% |
+500,000
| New | +$6.68M |
|
|
VRAY
16
DELISTED
ViewRay, Inc.
VRAY
| $6.61M | 2.72% |
1,200,000
-400,000
| -25% | -$2.44M |
|
|
CALY
17
Callaway Golf Company
CALY
$3.26B
| $5.49M | 2.26% |
200,000
-250,000
| -56% | -$6.94M |
|
18
Merck
MRK
$324B
| $5.37M | 2.21% |
+70,000
| New | +$5.58M |
|
19
McKesson
MCK
$98.5B
| $4.97M | 2.04% |
+20,000
| New | +$4.39M |
|
20
ScottsMiracle-Gro
SMG
$4.03B
| $4.83M | 1.99% |
+30,000
| New | +$4.64M |
|
21
Baxter International
BAX
$11.6B
| $4.29M | 1.76% |
+50,000
| New | +$4.02M |
|
22
CVS Health
CVS
$137B
| $4.13M | 1.7% |
+40,000
| New | +$3.7M |
|
23
Plexus
PLXS
$6.81B
| $4.03M | 1.66% |
42,000
+2,000
| +5% | +$185K |
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.76M | 1.55% |
225,000
-25,000
| -10% | -$410K |
|
|
MDRX
25
DELISTED
Veradigm Inc. Common Stock
MDRX
| $3.69M | 1.52% |
200,000
-375,000
| -65% | -$5.96M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2021 Portfolio in Review
As of Q4 2021, Tamarack Advisers held 62 positions worth $243M, down 23% from $317M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Tamarack Advisers withdrew a net $66.1M in Q4 2021, closing 14 positions and reducing 19 holdings. Its most notable exit was Misonix Inc, an estimated $10.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Humana worth $9.28M.
- Tamarack Advisers's largest Q4 2021 buy was Humana: 20,000 shares worth $9.28M.
- Tamarack Advisers added most to Tenet Healthcare in Q4 2021, an estimated $9.14M increase.
- Tamarack Advisers's biggest Q4 2021 reduction was Henry Schein, cutting an estimated $27.7M.
- Tamarack Advisers fully exited Misonix Inc in Q4 2021, selling an estimated $10.1M.
- Tamarack Advisers's ten largest holdings make up 49% of its $243M portfolio in Q4 2021.
- Tamarack Advisers opened 17 new positions and closed 14 in Q4 2021.
- Tamarack Advisers's portfolio value fell 23% quarter-over-quarter to $243M.
Based on Tamarack Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.